Miromatrix Medical, Baxter announce collaborative ALF research agreement

Miromatrix Medical (MIRO) and Baxter (BAX) announced a collaborative research agreement to help support additional treatment options for patients with acute liver failure, or ALF, in need of organ support therapies. As part of the collaboration, Miromatrix has created a new liver therapy called miroliverELAP that combines a Miromatrix single-use bioengineered liver with Baxter’s PrisMax system. Miromatrix submitted an investigational new drug, or IND, application for miroliverELAP to the FDA in November 2022, which appears to be the first IND for a bioengineered organ. Miromatrix intends to commence a Phase I clinical trial using miroliverELAP to treat patients suffering from ALF, following FDA’s decision that the trial may proceed. Baxter is both a collaborator and shareholder of Miromatrix.